GLPwatch
Papers (10386)
Page 128 of 174, ranked by citation count.
- Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
- A Case of Dulaglutide-Induced Vaginal Bleed.
- Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
- An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.
- Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.
- Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients.
- Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.
- Acute GLP-1 Agonism Induces Arrhythmogenic Electrical Activity in Aged Mice Heart Through Impaired Cellular Na+ and Ca2+ Handlings: The Role of CK2 Hyperphosphorylation.
- The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
- The evolving world of GLP-1 agonist therapies for type 2 diabetes.
- Tirzepatide and Glycemic Control Metrics Using Continuous Glucose Monitoring in Older Patients with Type 2 Diabetes Mellitus: An Observational Pilot Study.
- The etiopathogenesis and management of obesity: The quintessential quincunx.
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
- Dopamine signalling in pancreatic islet cells and role in adaptations to metabolic stress.
- Oral semaglutide: an OASIS from injectables.
- In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
- [Incretin therapy and the metabolic syndrome].
- Protective roles of liraglutide against brain injury of streptozotocin induced diabetic rats.
- Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.
- Patient experiences with group consultations when treated with semaglutide for obesity: a qualitative case study in a Danish general practice.
- Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.
- Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
- Drugs and devices for weight management.
- Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.
- Integrating semaglutide into obesity management - a primary care perspective.
- Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
- Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.
- Semaglutide exposures reported to the NSW Poisons Information Centre: effects of social media marketing and supply chain disruptions.
- [Incretin therapies and multifactorial clinical approach to cardiometabolic patients].
- Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.
- Exendin-4, a glucagon-like peptide receptor agonist, facilitates osteoblast differentiation via connexin43.
- Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
- Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation.
- [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
- Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
- Gateways to clinical trials.
- The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.
- Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.
- Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice.
- An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner's glands in mice.
- Liraglutide is an effective drug for the treatment of obesity also in real life.
- Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
- Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence.
- Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.
- GLP-1RA Reduces Supraspinatus Fatty Infiltration and Promotes Functional Recovery in a Rat Model of Rotator Cuff Repair.
- Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.
- Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs.
- Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide.
- The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.
- Liraglutide and systolic blood pressure.
- Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study.
- A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach.
- Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.
- Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.